Page 2287 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 136 Inhibitors in Hemophilias 2033.e1

REFERENCES 25. Pandev GS, Yanover C, Miller-Jenkins LM, et al and the PATH
Study Investigators: Synthesis of FVIII in Hemophilia A patients with
1. Lawrence JS, Johnson JB: The presence of a circulating anti-coagulant the intron-22-inversion may modulate immunogenicity. Nat Med
in a male member of a hemophiliac family. Trans Am Clin Climatol 19:1318–1324, 2013.
Assoc 57:223, 1941. 26. Astermark J, Oldenburg J, Pavlova A, et al: Polymorphisms in the
2. Munro FL, Jones HW: The detrimental effect of frequent transfusions IL-10 but not in the IL1Beta and IL4 genes are associated with
in the treatment of a patient with hemophilia. Am J Med Sci 206:710, inhibitor development in patients with haemophilia A. Blood 107:3167,
1943. 2006.
3. Munro FL, Munro MP: Electrophoretic isolation of a circulating 27. van der Bom JG, Mauser-Bunschoten EP, Fischer K, et al: Age at first
anticoagulant. J Clin Invest 25:814, 1946. treatment and immune tolerance to factor VIII in severe hemophilia.
4. Munro FL: Properties of an anticoagulant found in the blood of a Thromb Haemost 89:475, 2003.
hemophiliac. J Clin Invest 25:422, 1946. 28. Goudemand J, Rothschild C, Demiguel V, et al: Influence of the type
5. Craddock CG, Jr, Lawrence JS: A report of the mechanism of the of factor VIII concentrate on the incidence of factor VIII inhibitors in
development and action of an anticoagulant in two cases. Blood 2:505, previously untreated patients with severe hemophilia A. Blood 107:46,
1947. 2006.
6. Bidwell E, Denson KW, Dike GW: Antibody nature of the inhibitor 29. Hay CR: The epidemiology of factor VIII inhibitors. Haemophilia
to antihaemophilic globulin (factor 8). Nature 210:746, 1966. 12:23, 2006.
7. Oldenburg J, Schroeder J, Brackmann HH, et al: Environmental and 30. Santagostino E, Mancuso ME, Rocino A, et al: Environmental risk
genetic factors influencing inhibitor development. Semin Hematol factors for inhibitor development in children with haemophilia A: A
41:82, 2004. case-control study. Br J Haematol 130:422, 2005.
8. Schwaab R, Brackmann HH, Meyer C, et al: Haemophilia A: Mutation 31. Varon D, Martinowitz U: Continuous infusion therapy in haemophilia.
type determines risk of inhibitor formation. Thromb Haemost 74:1402, Haemophilia 4:431, 1998.
1995. 32. Sharathkumar A, Lillicrap D, Blanchette VS, et al: Intensive exposure to
9. Key NS: Inhibitors in congenital coagulation disorders. Br J Haematol factor VIII is a risk factor for inhibitor development in mild hemophilia
127:379, 2004. A. J Thromb Haemost 1:1228, 2003.
10. Ingerslev J: Hemophilia. Strategies for the treatment of inhibitor 33. ter Avest PC, Fischer K, Mancuso ME, et al On behalf of the Canal
patients. Haematologica 85:15, 2000. Study Group: Risk stratification for inhibitor development at first treat-
11. Hay CRM, Palmer B, Chalmers E, et al on behalf of the United ment for severe haemophilia A: a tool for clinical practice. J Thromb
Kingdom Hemophilia Centre Doctor’s Organisation (UKHCDO): Haemost 6:2048, 2008.
Incidence of FVIII inhibitors throughout life in severe haemophilia A 34. Elalfy MS, Elbarbary NS, Eldebeily MS, et al: Risk of bleeding and
in the United Kingdom. Blood 117:6367, 2011. inhibitor development after circumcision of previously untreated or
12. UK Haemophilia Centre Doctors’ Organisation. The incidence of FVIII minimally treated severe hemophilia A children. Pediatr Hematol Oncol
and FIX inhibitors in the hemophilia population of the UK and their effect 29:485–493, 2012.
on subsequent mortality, 1977-99. 35. Lusher JM: Is the incidence and prevalence of inhibitors greater with
13. Darby SC, Kan SW, Spooner RJ, et al: Mortality rates, life expectancy recombinant products? No. J Thromb Haemost 2:863, 2004.
and causes of death in people with haemophilia A or B in the United 36. Aledort LM: Is the incidence and prevalence of inhibitors greater with
Kingdom who were not infected with HIV. Blood 110:815, 2007. recombinant products? Yes. J Thromb Haemost 2:861, 2004.
14. Astermark J, Berntorp E: Malmo International Brother Study (MIBS). 37. Schwartz RS, Abildgaard CF, Aledort LM, et al: Human recombinant
An international survey of brother pairs with haemophilia. Vox Sang DNA-derived antihemophilic factor (factor VIII) in the treatment of
77:80, 1999. hemophilia A. Recombinant Factor VIII Study Group. N Engl J Med
15. Astermark J, Berntorp E, White GC, et al: The Malmo International 323:1800, 1990.
Brother Study (MIBS): Further support for genetic predisposition to 38. Bray GL, Gomperts ED, Courter S, et al: A multicenter study of recom-
inhibitor development in hemophilia patients. Haemophilia 7:267, binant factor VIII (Recombinate): Safety, efficacy, and inhibitor risk
2001. in previously untreated patients with hemophilia A. The Recombinate
16. Gill F: The natural history of factor VIII inhibitors in patients with Study Group. Blood 83:2428, 1994.
hemophilia A. In Hoyer LW, editor: Factor VIII Inhibitors: Proceedings of 39. Lusher J, Abildgaard C, Arkin S, et al: Human recombinant DNA-
an International Symposium Held in Farmington, Connecticut, Springer derived antihemophilic factor in the treatment of previously untreated
Berlin, 1984, Heidelberg, p 19. November 3-5, 1983. patients with hemophilia A: Final report on a hallmark clinical investi-
17. Addiego JE, Kasper CK, Abildgaard CF, et al: Increased frequency of gation. J Thromb Haemost 2:574, 2004.
inhibitors in African American hemophilia A patients (abstr). Blood 40. Gruppo R, Chen H, Schroth P, et al: Safety and immunogenicity of
84:239a, 1994. recombinant factor VIII (Recombinate) in previously untreated patients
18. Aledort LM, Dimichele DM: Inhibitors occur more frequently in (PUPs): A 7.3 year update (abstr). XXIII Congress of the WFH, The
African-American and Latino haemophiliacs. Haemophilia 4:68, Hague. Haemophilia 4:228, 1998.
1998. 41. Brinkhous K, Roberts HR, Weiss A: Prevalence of inhibitors in hemo-
19. Scharrer I, Bray GL, Neutzling O: Incidence of inhibitors in hae- philia A and B. Thromb Diath Haemorrh Suppl 51:315, 1972.
mophilia A patients: A review of recent studies of recombinant and 42. Iorio A, Hallmeh S, Holzhauer S, et al: Rate of inhibitor development
plasma-derived factor VIII concentrates. Haemophilia 5:145, 1999. in previously untreated hemophilia A patients treated with plasma-
20. Viel KR, Ameri A, Abshire TC, et al: Inhibitors of factor VIII in black derived or recombinant factor VIII concentrates: a systematic review.
patients with hemophilia. N Engl J Med 360:1618, 2009. J Thromb Haemost 8:1256, 2010.
21. Gouw SC, van den Berg HM, Oldenburg J, et al: F8 gene mutation 43. Mauser-Bunschoten EP, vander Born JG, Bongers M, et al: Purity of
type and inhibitor development in patients with severe haemophilia A: factor VIII product and incidence of inhibitors in previously untreated
systemic review and meta-analysis. Blood 119:2922, 2012. patients with haemophilia A. Haemophilia 7:364, 2001.
22. Oldenburg J, Pavlova A: Genetic risk factors for inhibitors to factors 44. Klukowska A, Komrska V, Jansen M, et al: Low incidence of FVIII
VIII and IX. Haemophilia 12S:15, 2006. inhibitors in previously untreated patients during prophylaxis. On
23. Oldenburg J, Schroder J, Brackmann HH, et al: Environmental and demand and surgical procedures, with Octanate: interim report from
genetic factors influencing inhibitor development. Semin Hematol ongoing prospective clinical study. Haemophilia 17:399, 2011.
41:82, 2004. 45. Gouw SC, van der Born JG, Auerswald G, et al: Recombinant versus
24. Sauna ZE, Lozier JN, Kasper CK, et al: The intron-22-inverted F8 plasma-derived factor VIII products and the development of inhibitors
locus permits factor VIII synthesis: explanation for low inhibitor risk in previously untreated patients with severe haemophilia A: the CANAL
and a role for pharmacogenomics. Blood 125:223–228, 2015. Cohort Study. Blood 109:4693, 2007.